Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and future outlook.

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity. Read why I rate NVO stock a Buy ...

Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries, has appointed Maziar Mike Doustdar as its new president and chief ...

Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure ...

He assumes the role as Novo struggles to become more competitive again. The drugmaker on Tuesday also cut its 2025 growth outlook, saying it now expects sales to grow from 8% to 14% and operating ...

Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition ...

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price. He first will need to win over sceptical ...